NCT00676429 - Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Conduct DisorderOppositional Defiant Disorder

Interventions

DRUG

Ziprasidone Hydrochloride

Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d

DRUG

Placebo

Placebo as oral solution, individually titrated

Trial Locations (1)

University Hospital Freiburg, Dep. for Child & Adolescent Psychiatry, Freiburg im Breisgau